The Evolving Future of PCSK9 Inhibitors

Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies that target PCSK9 lower LDL cholesterol (LDL-C) levels by 55% to 72% in different high-risk patient groups. Clinical trials...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology 2018-07, Vol.72 (3), p.314-329
Hauptverfasser:	Rosenson, Robert S., Hegele, Robert A., Fazio, Sergio, Cannon, Christopher P.
Format:	Artikel
Sprache:	eng
Schlagworte:	acute coronary syndrome Acute coronary syndromes Arteriosclerosis Atherosclerosis atherosclerotic cardiovascular disease Cardiology Cardiovascular diseases Cholesterol Clinical outcomes Clinical trials Coronary artery Coronary artery disease Diabetes Disease prevention Genes Heart diseases Inhibitors Kexin Low density lipoprotein Medical research Monoclonal antibodies Mutation Patients peripheral arterial disease Proprotein convertases Risk groups Statins Subtilisin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!